digital hypertension therapy app receives insurance support, sells service to healthcare institutions in Japan, launches September 1

Support lifestyle modification to treat hypertension

TOKYO, November 02, 2022–(BUSINESS WIRE)–CureApp, Inc. (Headquarters: Chuo-ku, Tokyo; CEO: Kohta Satake) announces the start of insurance coverage for its complementary high blood pressure treatment app CureApp HT (hereafter, CureApp HT), a DTx solution*1 for the treatment of hypertension in Japan from September 1, 2022. In the future, the app will be prescribed and provided to patients with hypertension as a treatment covered by Medicare in healthcare institutions .

This press release contains multimedia elements. See the full press release here:

Assisting Lifestyle Changes as a Treatment for Hypertension (Graphic: Business Wire)

After confirming the efficacy and safety of CureApp HT through clinical trials, the results of a Phase III Japanese nationwide multicenter randomized controlled trial have been published in EHJ, one of the peer-reviewed journals most respected in the world in 2021. In April 2022, CureApp HT was the world’s first digital hypertension therapy app to receive government approval, and the app has been supported by insurance since April 2022. September 1st. This is the first time in the world that a DTx treatment solution in the field of hypertension has been covered by insurance. Subsequently, CureApp will continue its efforts to market this medical innovation originating in Japan. The consequences of hypertension are known beyond Japan’s borders, and efforts to correct patients’ lifestyles are a recurring theme around the world. Therefore, CureApp also plans to proactively expand the reach of CureApp HT worldwide, starting with the United States.

Significance of lifestyle change, current challenges and potential of CureAppHT

The Rules for the Management of Hypertension 2019 describe that “lifestyle changes are not only important because they can have a hypotensive effect, but also because they prevent hypertension”. The rules also state that “lifestyle counseling should be provided to all patients with hypertension, as it may increase the hypotensive effect and reduce the dosage of hypotensive drugs.” Despite this recommendation, this type of behavioral treatment has struggled to take off due to the difficulty of enforcing lifestyle changes on patients on an ongoing basis and the limited duration of consultations with the physician. It is also said that a certain period of guided intervention*2 is necessary for lifestyle changes to take root.
CureApp HT helps connect physicians and patients, and promotes lifestyle changes that were previously difficult to maintain, while ensuring the maintenance of changed behavior in patients.

*1 Abbreviation for Digital Therapeutics. Products approved for use as medical devices.
*2 Kamioka H, ​​Nakamura Y, Yazaki T, Uebaba K, Mutoh Y, Okada S, Takahashi M. Comprehensive health education combining hot spa bathing and lifestyle education in middle-aged and elderly women: one-year follow-up on randomized controlled trial of three- and six-month interventions. J Epidemiol. 2006 Jan;16(1):35-44. doi: 10.2188/jea.16.35. PMID: 16369107; PMC ID: PMC7560544.

Summary of clinical trials for this product

About CureApp, Inc.

CureApp, Inc. is a medical technology company that conducts research and development aimed at creating medical device software that uses advanced software technology and medical evidence to treat disease. Its purpose is to manufacture and distribute them. The company is dedicated to the development of therapeutic apps, i.e. apps used to treat illnesses, to become the first in Japan to offer a new health service centered on “obtaining a therapeutic effect to treat diseases using an app”. In August 2020, CureApp was the first company in Japan to obtain medical device regulatory approval for a disease treatment app, in this case a nicotine addiction treatment app, which subsequently obtained medical device approval. approval for reimbursement by health insurance in December of the same year.

Companies in which CureApp is involved

Nicotine addiction

Regulatory approval as a medical device in August 2020; reimbursement by health insurance and start of prescriptions from December 2020


Regulatory approval as a medical device in April 2022


(non-alcoholic steatohepatitis)

In co-development with Sawai Group Holdings Co. /

Ongoing clinical trials with Tokyo University Hospital

Alcohol addiction

App under development with the national hospital organization Kurihama Medical and Addiction Center /

Clinical trials underway at Okayama City General Medical Center, Okayama City Hospital


Treatment app for breast cancer patients currently under development with DAIICHI SANKYO COMPANY, LIMITED.

Chronic heart failure

App under development with our partners at YUMINO Medical Corporation

In addition, we offer mobile health programs to private companies through our “ascure Smoking Cessation Programme” and our “ascure Specific Medical Support Program for Smoking Cessation”, which harness the knowledge acquired in the development of these digital therapies for healthcare establishments. These programs have been implemented in more than 230 companies and health insurance companies. In the future, we will successively deploy this “Japan-developed digital health solution” around the world, based on the model established in Japan.

CureApp, Inc Company Profile

representative and

Kohta Satake

The head office

Kodenma-Cho YS building 4th floor 12-5, Nihonbashi Kodenma-Cho, Chuo-ku, Tokyo, Japan, 103-0001

US branch

CureApp North America, Inc.


Development of SaMD (Software as a Medical Device) and mobile health-related services


The text of the press release resulting from a translation should in no way be considered official. The only authentic version of the press release is that of the press release in its original language. The translation will always have to be compared with the source text, which will set a precedent.

View the source version on


[ Renseignements ]
PR Manager, CureApp, Inc. (Mishima)

Leave a Comment